Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking great here to anyone who may be in. Either covering or a fund buying.
Regardless good for anyone long
Genitope Corp. $ 0.07
GTOP 0.02
Short Interest (Shares Short) 3,972,900
Days To Cover (Short Interest Ratio) 28.8
Short Percent of Float 17.99 %
Short Interest - Prior 3,987,300
Short % Increase / Decrease -0.36 %
Short Squeeze Ranking™ -511
% From 52-Wk High ($ 77.50 ) -9999.99 %
% From 52-Wk Low ($ 0.04 ) 42.86 %
% From 200-Day MA ($ 0.33 ) -371.43 %
% From 50-Day MA ($ 0.07 ) 0.00 %
Price % Change (52-Week) -98.70 %
Shares Float 22,080,000
Total Shares Outstanding 42,984,226
% Owned by Insiders 53.46 %
% Owned by Institutions 19.70 %
Market Cap. $ 2,991,702
Trading Volume - Today 270,024
Trading Volume - Average 138,000
Trading Volume - Today vs. Average 195.67 %
Earnings Per Share -2.45
PE Ratio
Record Date 2008-JulyA
Sector Healthcare
Industry Biotechnology
LOL.
By your transparent posting style I know you are Just2ice off of the cesspool yahoo forums.
Go work for a real hedge and not this fisher price one.
GTOP is going to file the CH11 very soon based on Yahoo Finance...
GTOP is extremely oversold and undervalued at $0.05. The OS is only
42.9M shares. Plus it is a Nasdaq listed stock. The target price
(given by the rating agency) is $0.26 which is very realistic goal.
This pos scam will soon be delisted from the Nasdaq exchange and must go to the Pink Sheets. The OS is diluting in large and soon
will hit 45M shares. All the business plan are failed. CH11 soon.
sold on yesterday's run
i was happy to make such a quick, quick profit
i'd rather pay short term taxes than hold and possibly take a loss
looks like it will trade under a dime once again
seems like a good buyout target for the pipeline and possible approval in Europe
It was overbought when GTOP hit $0.18 yesterday. $0.07 ~ $0.08
will be the good price to buy even there is uncertain risk ahead.
GTOP - once it cracks .14, it should do just fine
GTOP is in the up mood. My prediction target is $0.2 ~ $0.22 in a
week. I am glad to have bought more than 1M shares below $0.08.
closed at .23 - NO idea what its worth but sure down a lot
GTOP down in afterhours .16-.5707 cents 203,190 traded.
WOW! 7800 x 77.50 = 604,500.00 bucks . someone has money. 15:01:17 is the time it went off or they have fat fingers. LOL
*GTOP* Nice post...
BAC will presumably purchase CFC for about $6.5o PS although I have my doubt that this merger will go through mainly because of the tons of bonds issued by CFC. Still, the question remains, how is it that BAC is willing to pay $6.5o PS for an entity destined to go BK within days?
IMO, it all boils down to "intrinsic valore." Obviously, the marketplace was close to assigning zero value for the common shares of CFC while BAC came up with an intrinsic value much higher than the then prevailing share price.
I see the very same approach developing with GTOP. Current share price is significantly lower than the intrinsic valore of the comapania, therefore offers a tremendous value at these levels given that GTOP has no bonds outstanding, not yet anyway.
The investor would be wise to consider two important parameters with GTOP:
1. The tangible BV stands at $2.85 as published in various financial reports; and
2. GTOP has accumulated tax-loss-carry-forward of approximately $25oM, of which, according to Madam, is worth $1ooM in current market environment to a potential profitable buyer.
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_G/threadview?m=tm&bn=23603&tid=11057&mid=11057&tof=3&frt=2
LOOKS like the SHORTS knew it was coming!!!!!1
A Biotech Triple Catalyst Play
By: Mike Havrilla at www.mikehav.com/blog.html & www.mikehav.com
Disclosures: None
As 2007 winds down, investors in Genitope (GTOP) are keyed up for the final results of its experimental, personalized cancer immunotherapy treatment MyVax in the treatment of B-cell non-Hodgkin’s lymphoma. Results are expected some time this month, so the wait should not be much longer in what has been a long ride for the Company and its investors as two previously planned interim analyses failed to halt the trial early and demonstrate convincing effectiveness for MyVax. The most recent interim analysis of July 2006 was especially disheartening as the Company had expected to achieve statistical significance at that point for MyVax that would have allowed for an early end to the trial, but instead resulted in a tanking stock price from the $6 range to around $2 per share. Shares have since recovered, most recently trading around $3.50 per share with increasing volumes and volatility in anticipation of the make-or-break MyVax results due any day now. The most recent tally of short interest reveals a brazenly bearish stance with just over 11 million shares held short, which equates to about 26% of all shares outstanding and about 39% of the float. The opinion of analysts following the stock also varies widely from a low target of just $1 to a high of $17.50 per share.
Genitope files for $125 mln mixed shelf offering
Fri Oct 19, 2007 6:19am EDT
Oct 19 (Reuters) - Genitope Corp (GTOP.O: Quote, Profile, Research) said on Friday it may periodically sell up to $125 million in debt securities, common and preferred stock, warrants, depositary shares, rights, and units.
The biotechnology company, in a regulatory filing, said it may use the proceeds to acquire or invest in businesses, products and technologies.
Under a shelf registration filed with the U.S. Securities and Exchange Commission, a company may sell securities in one or more separate offerings with the size, price and terms to be determined at the time of sale. (Reporting by Savitha Kalyanaraman in Bangalore)
Cancer Vaccines Begin to Show Promise
By Malin Rising
Word Count: 955 | Companies Featured in This Article: Sanofi-Aventis, Roche Holding , GlaxoSmithKline, Merck KGaA, Genitope, Antigenics
COPENHAGEN -- After more than 20 years of setbacks, research into therapeutic cancer vaccines is starting to show promising results and attract the investments of large pharmaceutical firms. But the field remains risky, and so far no drugs have been approved for use.
About eight million people die from cancer each year, a figure that is expected to rise by 50% to approximately 12 million in 2030, making it the world's largest single killer disease, according to the World Health Organization.
Therapeutic vaccines stimulate the body's immune system to attack cancerous cells and leave healthy cells alive, while more traditional ...
also
Cancer Vaccines Attract Interest of Big Drug Firms
By Malin Rising
Word Count: 971 | Companies Featured in This Article: Sanofi-Aventis, Roche Holding , GlaxoSmithKline, Merck KGaA, Genitope, Antigenics
After more than 20 years of setbacks, research into therapeutic cancer vaccines is starting to show promising results and attract the investments of large pharmaceutical firms. But the field remains risky, and so far no drugs have been approved for use.
About eight million people die from cancer each year, a figure that is expected to rise by 50% to approximately 12 million in 2030, making it the world's largest single killer disease, according to the World Health Organization.
Therapeutic vaccines stimulate the body's immune system to attack cancerous cells and leave healthy cells alive, while more traditional cancer treatments ...
Genitope Corporation Announces Financial Results for Second Quarter Ended June 30, 2007
Genitope Corporation (NASDAQ: GTOP) today reported financial results for the second quarter ended June 30, 2007.
Financial Results
For the second quarter of 2007, Genitope Corporation (“Company”) reported total operating expenses of $16.4 million and a net loss of $17.0 million, or $0.42 per share. This compares to total operating expenses of $13.0 million and a net loss of $11.8 million, or $0.33 per share, for the second quarter of 2006. For the six months ended June 30, 2007, the Company reported total operating expenses of $30.9 million and a net loss of $32.2 million, or $0.85 per share, which compares to total operating expenses of $24.8 million and a net loss of $22.7 million, or $0.66 per share, for the six months ended June 30, 2006.
The increase in operating expenses for the second quarter of 2007 and the six months ended June 30, 2007 was primarily due to higher staffing levels and other operating costs required to support the Company's ongoing preparations to commercialize MyVax® personalized immunotherapy and the development of our monoclonal antibody program, as well as recognition of higher depreciation expenses associated with the Company’s manufacturing facility and corporate headquarters. The decrease in net interest income/expense reported for the second quarter of 2007 and the six months ended June 30, 2007 was primarily due to non-cash interest expense related to our manufacturing facility and corporate headquarters of $1.2 million and $2.3 million, respectively.
As of June 30, 2007, Genitope Corporation had cash, cash equivalents and marketable securities of $53.8 million, including $1.0 million that secures letters of credit which guarantees rental obligations under the lease for its manufacturing facility and corporate headquarters and is restricted as to its use. The decrease from the comparable balance at December 31, 2006 of $61.3 million (including $9.6 million that secured letters of credit related to the construction build-out costs of the Company’s manufacturing facility and corporate headquarters and was restricted as to its use) was primarily due to operating expenses and the capital expenditures required to complete the Company’s manufacturing facility and corporate headquarters, offset to a significant extent by the completion, in May of 2007, of a follow-on public offering of 6,010,279 shares of common stock at a price of $3.85 per share, with net proceeds to the Company of approximately $21.9 million.
2007 Corporate Progress and Outlook
“We remain optimistic that the final analysis of our Phase 3 trial will show a statistically significant benefit in progression-free survival for the patients receiving MyVax® personalized immunotherapy over the patients receiving the control substance,” said Dan Denney, Jr., Ph.D., Genitope Corporation's chairman and chief executive officer. “Additionally, we are continuing to move forward with our plans to commercialize MyVax® personalized immunotherapy.”
Mr. Denney further added, “We are pleased to have completed the public offering of common stock in May, 2007, resulting in net proceeds to Genitope of approximately $21.9 million. We believe that the net proceeds from the offering combined with our existing cash, cash equivalents and marketable securities, will provide us with sufficient financial resources to support our current plans for the development of both MyVax® personalized immunotherapy and our monoclonal antibody program into the middle of 2008.”
About Genitope Corporation
Genitope Corporation (Fremont, Calif.) is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation's lead product candidate, MyVax® personalized immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells. For more information on the company, please log on to http://www.genitope.com.
Forward-Looking Statements
This news release contains “forward-looking statements.” For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements, including but not limited to statements about the potential of the final analysis of the Phase 3 trial to show a statistically significant benefit in progression-free survival for patients receiving MyVax® personalized immunotherapy over the patients receiving the control substance and the adequacy of our existing cash, cash equivalents and marketable securities to provide us with sufficient financial resources to support our current plans for the development of MyVax® personalized immunotherapy and our monoclonal antibody program into the middle of 2008. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Genitope Corporation's results to differ materially from those indicated by these forward-looking statements, including without limitation, risks related to the progress, timing and results of Genitope Corporation's clinical trials, difficulties or delays in obtaining regulatory approval, unanticipated expenditures or liabilities, competition from other pharmaceutical or biotechnology companies, the risks of growth and dependence on key personnel, risks relating to the manufacturing of MyVax® personalized immunotherapy, intellectual property matters, and other risks detailed in Genitope Corporation's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter year ended March 31, 2007. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genitope Corporation undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
GENITOPE CORPORATION
(A DEVELOPMENT STAGE ENTERPRISE)
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
Cumulative
Deficit during
the Development
Stage Period
August 15, 1996
Three Months Ended Six Months Ended (date of inception)
June 30, June 30, to June 30,
2007 2006 2007 2006 2007
Operating expenses:
Research and development $ 13,205 $ 10,102 $ 25,025 $ 18,788 $ 166,199
Sales and marketing 728 608 1,197 1,442 11,364
General and administrative 2,445 2,242 4,722 4,609 30,871
Total operating expenses 16,378 12,952 30,944 24,839 208,434
Loss from operations (16,378 ) (12,952 ) (30,944 ) (24,839 ) (208,434 )
Loss on extinguishment of convertible notes and cancellation of Series E convertible preferred stock warrants
- - - - (3,509 )
Interest expense (1,289 ) - (2,607 ) (1 ) (6,779 )
Interest and other income 697 1,142 1,352 2,168 10,805
Net loss (16,970 ) (11,810 ) (32,199 ) (22,672 ) (207,917 )
Dividend related to issuance of convertible preferred shares and the beneficial conversion feature of preferred stock
- - - - (18,406 )
Net loss attributable to common stockholders $ (16,970 ) $ (11,810 ) $ (32,199 ) $ (22,672 ) $ (226,323 )
Basic and diluted net loss per common share attributable to common stockholders
$ (0.42 ) $ (0.33 ) $ (0.85 ) $ (0.66 )
Shares used in computing basic and diluted net loss per share attributable to common stockholders
39,950 35,873 38,012 34,178
GENITOPE CORPORATION
(A DEVELOPMENT STAGE ENTERPRISE)
UNAUDITED CONDENSED BALANCE SHEETS
(in thousands, except per share and share data)
June 30, 2007 December 31, 2006
ASSETS
Current assets:
Cash, cash equivalents and marketable securities $ 52,836 $ 51,682
Prepaid expenses and other current assets 2,747 3,312
Total current assets 55,583 54,994
Restricted cash and marketable securities 1,000 9,579
Property and equipment, net 91,940 93,479
Other assets 2,006 2,371
Total assets $ 150,529 $ 160,423
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 2,358 $ 5,551
Accrued and other current liabilities 4,009 4,814
Current portion of credit line 1,912 1,662
Total current liabilities 8,279 12,027
Lease financing liability and accrued interest 44,555 41,941
Noncurrent portion of credit line 3,045 3,609
Total liabilities 55,879 57,577
Stockholders' equity
Common stock, $0.001 par value, 65,000,000 shares authorized; Issued and outstanding: 42,082,074 shares at June 30, 2007 and 36,052,685 shares at December 31, 2006
42 36
Additional paid-in capital 320,956 296,962
Deferred stock compensation (2 ) (19 )
Accumulated other comprehensive loss (23 ) (8 )
Deficit accumulated during development stage (226,323 ) (194,125 )
Total stockholders' equity 94,650 102,846
Total liabilities and stockholders' equity $ 150,529 $ 160,423
Investors:
Genitope Corporation
John Vuko, 510-284-3000
IR@genitope.com
or
Media:
Edelman
Marites Cristobal, 323-202-1424
marites.cristobal@edelman.com
Source: Business Wire (August 7, 2007 - 7:39 AM EST)
News by QuoteMedia
www.quotem
Genitope (GTOP - Cramer's Take - Stockpickr)
Drug: MyVax
Indication: B cell non-Hodgkin's lymphoma
Results expected: Fourth quarter 2007
MyVax is another cancer "vaccine," and like Favrille's Favid, is being developed as a treatment for non-Hodgkin's lyphoma. Genitope has already conducted several interim analyses of its phase III MyVax study with no success, meaning that the data weren't sufficient to show a clinical benefit. Final results are expected before the end of the year.
Test Time
Positive results will provide a boost
Company Drug Indication Results expected Trial Name
Accentia Biopharmaceuticals SinuNase Anti-bacterial, Mycobacterial, or Fungal Q4 2007 Phase III
Actelion Pharmaceuticals Veletri Coronary Artery Bypass Graft (CABG) 2H 2008 Study 1
Actelion Pharmaceuticals Tracleer Idiopathic Pulmonary Fibrosis (IPF) 2H 2008
Advanced Life Sciences Cethromycin Community Acquired Pneumonia (CAP) Q3 2007 CL-05
Advanced Magnetics Ferumoxytol Anemia Due to Chronic Renal Failure, Dialysis-Dependent Q3 2007 Phase III - DD-CKD
Altus Pharmaceuticals ALTU-135 Exocrine Pancreatic Insufficiency Mid-2008 DIGEST - Efficacy
Amgen AMG 531 Immune Thrombocytopenic Purpura (ITP) Q4 2007 Extension Study
Amgen Denosumab Hypercalcemia of Malignancy/Metastatic Bone Complications 2008 Phase III - Prostate cancer prevention
Amgen Denosumab Osteoporosis / Osteopenia 2H 2007 Phase III - Postmenopausal prevention (132 Study)
Arena Pharmaceuticals Lorcaserin Obesity Q4 2008-Q1 2009 BLOOM
AtheroGenics AGI-1067 Diabetes Mellitus, Type II Q4 2008 ANDES
AVAX Technologies M-Vax Melanoma 2008 Phase III
BioDelivery Sciences International BEMA Fentanyl Pain Indications 2H 2007
Biogen IDEC Rituxan Systemic Lupus Erythematosus (SLE) Mid-2008
Biogen IDEC Rituxan Multiple Sclerosis (MS) 1H 2008 OLYMPUS
Cadence Pharmaceuticals IV APAP Pain Indications 1H 2008 CPI-APA-301
Cell Genesys GVAX Prostate Cancer Vaccine Prostate Cancer Q4 2008 VITAL-1
Cell Therapeutics Pixantrone Non-Hodgkin's Lymphoma (NHL) Q3 2007 EXTEND
Cell Therapeutics Xyotax Non-Small Cell Lung Cancer (NSCLC) Mid-2008 PGT307
Cell Therapeutics Xyotax Non-Small Cell Lung Cancer (NSCLC) 2H 2008 PGT306
Cell Therapeutics Xyotax Ovarian Cancer 2H 2008 Phase III - GOG
Cypress Bioscience Milnacipran Fibromyalgia 1H 2008 Phase III - Third Trial
Dendreon Provenge Prostate Cancer 1H 2008 IMPACT (D9902B - ALL Gleason Scores)
Favrille FavId Non-Hodgkin's Lymphoma (NHL) Q4 2007 FavId-06 (Phase III)
Genentech Avastin Breast Cancer 2008 AVADO (BO17708) - 1st Line
Genentech Avastin Breast Cancer Q4 2007 ECOG 2104
Genentech Avastin Renal Cell Cancer (RCC) Q3 2007 - Q2 2008 CALGB 90206
Genentech Avastin Pancreatic Cancer 2H 2007 AVITA (BO17706) - w/Tarceva + gemcitabine
Genentech Avastin Renal Cell Cancer (RCC) 2H 2007 Phase III - AVOREN (B017705)
Genitope MyVax Non-Hodgkin's Lymphoma (NHL) Q4 2007 Phase III (2000-03)
Genmab Ofatumumab Non-Hodgkin's Lymphoma (NHL) Q4 2007-1Q 2008 Phase III
Genmab HuMax-CD4 Cutaneous T-Cell Lymphoma (CTCL) 2008 Phase III (Pivotal)
Genta Genasense Small Cell Lung Cancer (SCLC) 2H 2007
Genzyme Clolar Acute Myelogenous Leukemia (AML) Q3 2007 AML 16 - Non-intensive
Genzyme Mozobil Bone Marrow Transplant Q3 2007 Phase III - NHL
Genzyme Mozobil Bone Marrow Transplant Q3 2007 Phase III - MM
GTC Biotherapeutics ATryn Anticoagulation Mid-2008 Phase II - DIC
GTC Biotherapeutics ATryn Anticoagulation Q4 2007 Phase III
GTx Acapodene Prostate Cancer Q1 2008 Phase III - ADT
GTx Acapodene Prostatic Intraepithelial Neoplasia (PIN) Q4 2007-Q1 2008 Phase III - Monotherapy
ImClone Systems Erbitux Non-Small Cell Lung Cancer (NSCLC) 2008 SELECT (IMCL-0452)
ImClone Systems Erbitux Non-Small Cell Lung Cancer (NSCLC) 2H 2007 FLEX (EMR-046)
ImClone Systems Erbitux Non-Small Cell Lung Cancer (NSCLC) 2H 2007 BMS-099 (Taxane)
Immtech Pharmaceuticals Pafuramidine maleate Anti-parasitic or other infectious disease 2H 2007 Phase III
Indevus Pharmaceuticals PRO 2000 HIV prevention Q4 2008-2009 Phase III (Europe)
Inspire Pharmaceuticals Denufosol tetrasodium Cystic Fibrosis 2008
InterMune Pirfenidone Idiopathic Pulmonary Fibrosis (IPF) Q4 2008-2009 CAPACITY 1
InterMune Pirfenidone Idiopathic Pulmonary Fibrosis (IPF) Q4 2008-2009 CAPACITY 2
Introgen Therapeutics Advexin Head and Neck Cancer 2H 2007 Trial 302 - with 5-FU
Introgen Therapeutics Advexin Head and Neck Cancer 2H 2007 Trial 301 - vs. Methotrexate
Keryx Biopharmaceuticals Sulonex Diabetic Nephropathy Q1 2008 Phase III
Lev Pharmaceuticals C1-INH-nanofiltered Hereditary angioedema (HAE) 2H 2007 LEVP2005-1: CHANGE Trial - Parts A and B
Ligand Pharmaceuticals Oporia Osteoporosis / Osteopenia 2H 2007 PEARL
MannKind Corporation Technosphere Diabetes Mellitus, Type II 2H 2008 Phase III (Study 103)
MannKind Corporation Technosphere Diabetes Mellitus, Type II 2H 2008 Phase III (Study 102)
MannKind Corporation Technosphere Diabetes Mellitus, Type I 2H 2008 Phase III (Study 009)
Medarex (with Johnson & Johnson) CNTO 1275 Psoriasis 2H 2007 Phase III
Medarex (with Bristol-Myers Squibb) Ipilimumab Melanoma 2008 Phase III - 1st Line with DTIC (SPA)
Medarex (with Bristol-Myers Squibb) Ipilimumab Melanoma 2H 2007 Phase II - 2nd Line monotherapy (SPA)
Medarex (with Johnson & Johnson) Golimumab Rheumatoid Arthritis (RA) 2008 T05 - Methotrexate-naive
Medarex (with Johnson & Johnson) Golimumab Rheumatoid Arthritis (RA) 2008 T06 - Methotrexate Non-responders
Medarex (with Johnson & Johnson) Golimumab Ankylosing Spondylitis 2008 T09
MGI Pharma AQUAVAN Anesthesia 2H 2007 Phase III - Bronchoscopy
MGI Pharma AQUAVAN Anesthesia 2H 2007 Phase III - Safety (Minor Surgeries)
Migenix Omigard Anti-bacterial, Mycobacterial, or Fungal 2H 2008 Phase III - CLIRS
Myriad Genetics. Flurizan Alzheimer's Disease (AD) Mid-2008 Phase III - 800mg US - mild
Neurobiological Technologies Viprinex Ischemic Stroke Q1 2008 ASP-I
Neurobiological Technologies Viprinex Ischemic Stroke Q1 2008 ASP-II
Neurochem Alzhemed Alzheimer's Disease (AD) 2H 2007 CL-758007 (North American)
Novacea Asentar Prostate Cancer 2008 ASCENT-2
Novogen Phenoxodiol Ovarian Cancer 1H 2008 OVATURE - Phase IIb/III
NPS Pharmaceuticals Teduglutide Short Bowel Syndrome (SBS) 2H 2007 Phase III - Safety and Efficacy Study
Onyx Pharmaceuticals Nexavar Non-Small Cell Lung Cancer (NSCLC) 2008 Phase III - Pivotal
Onyx Pharmaceuticals Nexavar Melanoma 2008 Phase III - ECOG2603
Optimer Pharmaceuticals OPT-80 Clostridium difficile associated Diarrhea (CDAD) 2008 Second Phase III
Optimer Pharmaceuticals OPT-80 Clostridium difficile associated Diarrhea (CDAD) 2008 PAR101.C.003
Osiris Therapeutics Prochymal Graft vs. Host Disease (GVHD) mid-2008 Steroid-Refractory
Pain Therapeutics Remoxy Pain Indications 2H 2007 Phase III - SPA
Poniard Pharmaceuticals Picoplatin Small Cell Lung Cancer (SCLC) Q4 2007 - Q1 2008 SPEAR
Progenics Pharmaceuticals Methylnaltrexone IV Postoperative Ileus 2H 2007 Phase III (1)
Replidyne Orapem Anti-bacterial, Mycobacterial, or Fungal 2H 2007 Phase III - Bronchitis
Repros Therapeutics Androxal Hypogonadism 1H 2008 Phase III
Salix Pharmaceuticals Xifaxan Clostridium difficile associated Diarrhea (CDAD) 1H 2008 Phase III vs. Vancocin
Salix Pharmaceuticals Xifaxan Hepatic Encephalopathy (HE) 1H 2008
Savient Pharmaceuticals Puricase Gout Q4 2007 GOUT 2
Savient Pharmaceuticals Puricase Gout 2H 2007 Phase II - Monotherapy
SciClone Pharmaceuticals Zadaxin Hepatitis C Q4 2007 Sigma-Tau EU Trial
Somaxon Pharmaceuticals Silenor Insomnia Q3 2007
Sonus Pharmaceuticals TOCOSOL Paclitaxel Breast Cancer Q3 2007 Phase III - Monotherapy
SuperGen Dacogen Acute Myelogenous Leukemia (AML) 2H 2007 DACO-016
The Medicines Company Cleviprex Hypertension (Systemic) Q3 2007 VELOCITY - severe
Theravance Telavancin Hospital Acquired (Nosocomial) Pneumonia (HAP) Q4 2007 ATTAIN 2
Theravance Telavancin Hospital Acquired (Nosocomial) Pneumonia (HAP) Q4 2007 ATTAIN 1
Threshold Pharmaceuticals Glufosfamide Pancreatic Cancer Q3 2007 Phase I/II - w/Gemcitabine
UCB Cimzia Psoriasis Q3 2007
United Therapeutics OvaRex Ovarian Cancer 2H 2007 IMPACT II
United Therapeutics OvaRex Ovarian Cancer 2H 2007 IMPACT I
United Therapeutics UT-15C Pulmonary Arterial Hypertension (PAH) Q3 2007 - Q1 2008 FREEDOM-M
United Therapeutics UT-15C Pulmonary Arterial Hypertension (PAH) Q3 2007 - Q1 2008 FREEDOM-C
Valeant Pharmaceuticals Retigabine Seizure Disorders 2H 2007 RESTORE 1 - N. America, Argentina, Brazil
Valeant Pharmaceuticals Retigabine Seizure Disorders 2H 2007 RESTORE 2 - EU, Israel, Australia, S. Africa
Vanda Pharmaceuticals VEC-162 Insomnia mid-2008
Genitope Corporation Initiates Clinical Trial to Evaluate Use of MyVax(R) Personalized Immunotherapy Following Treatment With Rituximab and Chemotherapy for Follicular Non-Hodgkin's Lymphoma
FREMONT, Calif., May 21 /PRNewswire-FirstCall/ -- Genitope Corporation (Nasdaq: GTOP) today announced the initiation of a Phase 2 clinical trial evaluating the use of MyVax(R) personalized immunotherapy following primary treatment with rituximab and chemotherapy (R-Chemo) for follicular non-Hodgkin's lymphoma (fNHL). MyVax(R) personalized immunotherapy is based on the unique genetic makeup of a patient's own tumor and is designed to activate the patient's immune system to fight cancer.
'This is an important trial because it will provide additional information on the optimal timing for use of MyVax(R) personalized immunotherapy following treatment with the current standard of care for patients with fNHL,' said Julie Vose, M.D., professor of medicine and chief of the Oncology/Hematology section, University of Nebraska Medical Center. 'Initial data have suggested that adding MyVax(R) personalized immunotherapy to the current treatment protocol may extend duration of remission while maintaining a well-tolerated safety profile. We are optimistic this therapy will provide another promising option for the treatment of non-Hodgkin's lymphoma.'
Genitope plans to enroll 100 patients in this multi-center, Phase 2, single-arm study at eight leading cancer centers across the United States, including the University of Nebraska Medical Center. The clinical trial is primarily designed to evaluate the efficacy and safety of MyVax(R) personalized immunotherapy following treatment with R-Chemo. Men and women ages 18 years or older who have been diagnosed with previously untreated fNHL, stage III or IV, and who require therapy and are able to receive rituximab and chemotherapy (cyclosphosphamide, vincristine and prednisone either with or without doxorubicin) may be eligible for the study. Eligible patients will receive six to eight cycles of R-Chemo, and after a six-month rest period, will receive a series of 24 immunizations with MyVax(R) personalized immunotherapy over a 92-week period.
'We continue to explore the optimal regimen for MyVax(R) personalized immunotherapy to induce a strong anti-tumor immune response in patients with fNHL,' said Mary Ellen Rybak, M.D., vice president of Medical Affairs and chief medical officer at Genitope Corporation. 'We hope that data from this Phase 2 trial will provide additional insight on the potential for MyVax(R) personalized immunotherapy to improve survival and alter the natural history of this disease.'
For more information about the trial and a complete list of open trial sites, individuals can call Genitope Corporation at 866-GENITOP or visit the company's Web site at www.genitope.com.
MyVax(R) personalized immunotherapy is currently in a pivotal, double-blind, controlled Phase 3 clinical trial to evaluate its safety and efficacy in previously untreated patients with fNHL. In this trial, patients first received chemotherapy to reduce their tumor burden, followed by a 6-month rest period. Patients who maintained at least a partial response through the rest period were then randomized to receive either MyVax(R) personalized immunotherapy or a non-specific immunotherapy, which serves as a control for this trial. Genitope Corporation enrolled 287 patients in this Phase 3 trial. The treatment phase is completed and the protocol-defined follow-up period of the clinical trial is scheduled to conclude at the end of 2007.
NHL is the most common cancer involving B-cells, and is the sixth most common cancer in the United States. There are currently more than 300,000 people in the country living with NHL, with 55,000 new cases diagnosed annually and approximately 32 percent of those diagnoses being new fNHL cases. In addition to clinical trials in fNHL, Genitope Corporation is also exploring the use of MyVax(R) personalized immunotherapy to treat other types of B-cell cancers, including patients with previously untreated chronic lymphocytic leukemia.
About Genitope Corporation
Genitope Corporation (Redwood City, Calif.) is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation's lead product candidate, MyVax(R) personalized immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells. For more information on the company, please log on to www.genitope.com.
Forward Looking Statements
This news release contains 'forward-looking statements.' For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements, including statements regarding the potential of MyVax(R) personalized immunotherapy to extend the duration of remission, improve survival or alter the natural history of follicular non-Hodgkin's lymphoma. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'will,' 'intends' and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Genitope Corporation's results to differ materially from those indicated by these forward-looking statements, including without limitation, risks related to the progress, timing and results of Genitope Corporation's clinical trials, risks related to competition from other pharmaceutical or biotechnology companies, the risks of growth and dependence on key personnel, risks relating to the manufacturing of MyVax(R) personalized immunotherapy and other risks detailed in Genitope Corporation's filings with the Securities and Exchange Commission, including the Annual Report or Form 10-K for the fiscal year ended December 31, 2006. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genitope Corporation undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Media Contact:
Marites Cristobal
P: 323.202.1424
C: 415.819.2214
marites.cristobal@edelman.com
Investor Contact:
John Vuko
Chief Financial Officer, Genitope
P: 650.482.2000
IR@genitope.com
SOURCE Genitope Corporation
This has been a very nice bonuce back stock since the dump a few weeks ago.....Still holding...
GL
GTOP -2.61- Gap to Fill
Running commentary TA-wise will be maintained at 'TA Or Die'.
Kaplan-Meier curve reflecting the probability of progression-free survival (PFS) generated from the blinded data (including data from patients who received MyVax®personalized immunotherapy and from patients who received the control substance) for all 287 randomized patients enrolled in Genitope Corporation's pivotal Phase 3 clinical trial for MyVax®personalized immunotherapy in patients with previously untreated follicular B-cell Non-Hodgkin's lymphoma.
http://biz.yahoo.com/e/060801/gtop8-k.html
The last two candlesticks formed a Bullish Harami Pattern . This is a bullish reversal pattern that marks a potential change in trend. However, its reliability is low and it definitely requires confirmation.
>>>ROC shows GTOP was oversold<<<<<
Genitope Corp. (GTOP): the Redwood City, CA based biotechnology company was left behind the strong market rally as it instead plummetted 48.57% to all time low of $2.87 per share on analyst downgrade as its data safety monitoring board recommended the study of the company's cancer drug would still need to keep going. It appears that the investors have lost faith on the development stage company as it still need to burn cash for couple of years before its drug went commercialized. Currently the company has 87 million in short term assets and with short term liabilities of 17 million and about 11 million net loss per quarter the company would need to raise cash again next year. However it's still too early for bankruptcy so this may actually be a good time to get some of the shares in huge discount as ROC shows the stock was oversold. The stock was the biggest loser on Nasdaq today with 7.57 million shares traded.
http://stockonthemove.blogspot.com/2006/07/stocks-on-move-july-28.html
Therapeutic approach of personalized immunotherapy and our lead product, MyVax® Personalized Immunotherapy (previously referred to as GTOP-99). The content includes:
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
91
|
Created
|
07/28/06
|
Type
|
Free
|
Moderators |
http://www.genitope.com/index.html
Weekly
Historical News Releases
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |